Log in to your account:
Pfizer (PFE) PT Lowered to $45 at BofA/Merrill Lynch
January 30, 2019 6:09 AM
BofA/Merrill Lynch analyst Jason Gerberry ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Analyst PT Change
Pfizer (PFE) Reports Positive CHMP Opinion for Vizimpro (dacomitinib) Positive CHMP Opinion for Vizimpro (dacomitinib) for 1st-Line Treatment of Adult Patients
February 1, 2019 9:21 AM